Compare Merck & Co., Inc. (MRK) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs OneSpan Inc — how do they compare? Merck & Co., Inc. trades at $132.51 (market cap $321.77B), while OneSpan Inc trades at $16.09 (market cap $600.69M). The key difference: Merck & Co., Inc. is far larger — about 535.7× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| MRK | OSPN | |
|---|---|---|
Market Cap | $321.77B | $600.69M |
Sector | Health | Technology |
52-Week High | $131.84 | $16.78 |
52-Week Low | $77.60 | $10.15 |
Enterprise Value | $368.53B | $569.77M |
Dividend Yield | 2.61% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
OneSpan (OSPN) trades at $16.21, down 0.98% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 9.21, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed revenue growth and raised full-year guidance, while the company continues paying $0.13 quarterly dividends.
Outlook remains positive with 67% analyst buy ratings and $17 consensus target offering 5% upside. Key risks include declining net cash flow and competitive pressures in the software sector. The stock presents value opportunity given attractive valuation multiples and strong profitability metrics, though investors should monitor execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
